Investigational Drug Information for Semaxanib
✉ Email this page to a colleague
What is the development status for investigational drug Semaxanib?
Semaxanib is an investigational drug.
There have been 27 clinical trials for Semaxanib.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2000.
The most common disease conditions in clinical trials are Sarcoma, Colorectal Neoplasms, and Sarcoma, Kaposi. The leading clinical trial sponsors are National Cancer Institute (NCI), Case Comprehensive Cancer Center, and Jonsson Comprehensive Cancer Center.
Summary for Semaxanib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 5,305 |
| WIPO Patent Applications | 1,030 |
| Japanese Patent Applications | 591 |
| Clinical Trial Progress | Phase 3 (2000-12-01) |
| Vendors | 78 |
Recent Clinical Trials for Semaxanib
| Title | Sponsor | Phase |
|---|---|---|
| Radiation Therapy With or Without SU5416 in Treating Patients With Soft Tissue Sarcoma | National Cancer Institute (NCI) | Phase 1/Phase 2 |
| Radiation Therapy With or Without SU5416 in Treating Patients With Soft Tissue Sarcoma | Radiation Therapy Oncology Group | Phase 1/Phase 2 |
| Chemotherapy, SU5416, Radiation Therapy, and Surgery in Treating Patients With Soft Tissue Sarcoma | National Cancer Institute (NCI) | Phase 1/Phase 2 |
Clinical Trial Summary for Semaxanib
Top disease conditions for Semaxanib
Top clinical trial sponsors for Semaxanib
US Patents for Semaxanib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
